Bivalirudin and eptifibatide's bleeding risks are evaluated in study

08/22/2013 | InternalMedicineNews.com (free registration)

Researchers at Mount Auburn Hospital in Massachusetts found that angioplasty patients who received bivalirudin had fewer but more severe bleeding episodes than those treated with eptifibatide. Among 345 patients who received eptifibatide, 20 had bleeding events, while 10 events were reported among 660 patients in the bivalirudin group, and in each group, seven of the episodes were considered severe.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX